ATS接受COVID-19疫苗注射器生产线订单，引入Symphoni™

剑桥/时间/- ATS Automation tools Systems Inc. (TSX:ATA)(“ATS”或“公司”)是行业领先的自动化解决方案提供商，今天宣布已从一家医疗设备制造商获得2000万美元的订单，以设计、建造和交付几个自动化安全注射器制造系统，这些系统将采用该公司的新型、高性能SymphoniTM技术。该计划将在未来10个月内完成，并将使安全注射器的生产能够满足与COVID-19疫苗生产相关的潜在需求。

ATS首席执行官Andrew Hider表示:“我们的团队仍然专注于帮助制造商解决COVID-19大流行带来的医疗设备的关键需求。”ATS参与这一关键项目，凸显了我们在生命科学领域的重要能力，以及我们通过包括Symphoni在内的先进技术，快速帮助制造商实现医疗器械行业所要求的最高质量水平的规模化生产的能力。”

该项目与美国政府的曲速行动有关，该行动旨在提高美国生产安全针头和注射器的能力。这一努力对于满足预期需求至关重要，因为常规卫生保健消耗了现有供应，并治疗了激增的COVID-19患者。ATS的Symphoni技术是紧急的、对时间敏感的程序的理想选择，例如“曲速行动”，因为它的标准化、模块化结构有助于其快速部署和可扩展的复制。

Symphoni
ATS的Symphoni专利技术将在这些注射器制造系统中占据显著地位。Symphoni是一种创新的、高性能的数字化制造技术，通过消除非增值生产时间，提高自动化装配过程的生产率。高度的标准化，模块化的构建块和即插即用的性质意味着symphony系统是通用的，多用途的生产资产，具有灵活性，以适应新产品和新工艺的整个使用寿命。因为symphony系统是数字化的，100%可编程的，所有的动作都被精确地描绘出来，并通过一种称为电子传动的技术实现同步，从而产生“运动交响曲”。Symphoni的高速、高精度和可配置灵活性的颠覆性组合预示着自动化装配的革命。它完美地满足了注射器等大容量消耗品的制造需求，因为它在紧凑的占地面积内以非常高的速度组装它们，同时确保符合医疗器械行业严格的质量标准。

关于美国胸科协会
ATS是行业领先的自动化解决方案提供商，为许多世界上最成功的公司提供解决方案。ATS利用其在定制自动化、重复自动化、自动化产品和增值服务(包括自动化前和售后服务)方面的广泛知识和全球能力，在生命科学、化工、消费品、电子、食品、饮料、交通、能源、石油和天然气。ATS成立于1978年，拥有约4,400名员工，在北美、欧洲、东南亚和中国设有22家生产工厂和50多个办事处。本公司的股票在多伦多证券交易所交易，代码为ATA。请访问公司网站www.atsautomation.com。

给读者的说明:前瞻性声明
本新闻稿包含适用证券法意义下构成前瞻性信息的某些声明(“前瞻性声明”)。这些前瞻性陈述涉及到已知和未知的风险、不确定性和其他因素，这些因素可能会导致ATS的实际结果、业绩或成就，或ATS业务或行业的发展，与ATS的预期结果、业绩有重大差异。这种前瞻性声明所表达或暗示的成就或发展。前瞻性陈述包括根据对未来经济状况和行动路线的假设，对业务可能发生的事件、条件或结果的所有披露。前瞻性陈述还可以包括但不限于与未来事件、条件或情况有关的任何陈述。前瞻性陈述除其他外，涉及宣布新的订单登记;预期的完成时间;和公司的新SymphoniTM技术。可能影响前瞻性陈述的风险和不确定性包括:COVID-19的发展及其对公司资产运营能力的影响，包括可能因COVID-19暴发而关闭设施;在公司开展业务的所有管辖区，COVID-19大流行的严重程度和持续时间; the nature and extent of government imposed restrictions on travel and business activities and the nature, extent, and applicability of government assistance programs, in both cases related to the COVID-19 pandemic, as applicable in all jurisdictions where the Company conducts its business; the impact of the COVID-19 pandemic on the Company's employees, customers, and suppliers; the impact of the global economy and general market performance; that the timing of completion of the program is other than as expected due to various reasons, including schedule changes or COVID-19 pandemic related factors; the customer exercising any right to terminate the program in whole or in part prior to its completion, thereby preventing ATS from realizing on the full benefit of the program; that the Company's new technology does not achieve wide-spread market acceptance or otherwise performs other than as expected; management effectiveness and disaster response preparedness, including business continuity plans in response to COVID-19; that one or more customers, or other entities with which the Company has contracted, experience insolvency or bankruptcy with resulting delays, costs or losses to the Company; political, labour or supplier disruptions; risks relating to legal proceedings to which ATS is or may become a party; exposure to product and/or professional liability claims; and other risks detailed from time to time in ATS' filings with Canadian provincial securities regulators. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on the forward-looking statements or information contained herein which speak only as of the date they are made. Forward-looking statements are based on management's current plans, estimates, projections, beliefs and opinions, and other than as required by applicable securities laws, ATS does not undertake any obligation to update forward-looking statements should assumptions related to these plans, estimates, projections, beliefs and opinions change.